1	Comparison of excess deaths and laboratory-confirmed COVID-19 deaths
2	during a large Omicron epidemic in 2022 in Hong Kong
3	Hualei Xin ^{1,2} , Alexandra H. T. Law ² , Justin K. Cheung ² , Yun Lin ² , Peng Wu ^{2,3} ,
4	Zhongjie Li ¹ , Benjamin J. Cowling ^{2,3} , Weizhong Yang ¹ , Jessica Y. Wong ²
5	
6	Affiliations:
7	1. School of Population Medicine and Public Health, Chinese Academy of Medical
8	Sciences & Peking Union Medical College, Beijing, China.
9	2. World Health Organization Collaborating Centre for Infectious Disease
10	Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of
11	Medicine, The University of Hong Kong, Hong Kong Special Administrative
12	Region, China
13	3. Laboratory of Data Discovery for Health Limited, Hong Kong Science and
14	Technology Park, New Territories, Hong Kong Special Administrative Region,
15	China
16	
17	Corresponding authors:
18	Peng Wu, School of Public Health, Li Ka Shing Faculty of Medicine, The University
19	of Hong Kong, 7 Sassoon Road, Pokfulam, Hong Kong.
20	Tel: +852 3917 6746; Fax: +852 3520 1945; email: pengwu@hku.hk
21	
22	Weizhong Yang, School of Population Medicine and Public Health, Chinese
23	Academy of Medical Sciences & Peking Union Medical College, 7 Dongdan
24	Santiao, Dongcheng District, Beijing, China.

- 27 **Running head:** Comparison of Excess deaths and COVID-19 deaths
- 28 Word count (abstract): 282
- 29 Word count (main text): 2,629
- 30 Key words: COVID-19, Excess mortality, laboratory-confirmed COVID-19
- 31 mortality, Omicron, Elimination
- 32
- 33

34 ABSTRACT

35	Background: Using a local elimination strategy, Hong Kong was able to minimize
36	COVID-19 mortality in 2020 and 2021, but a large epidemic caused by the Omicron
37	variant occurred in 2022. We aimed to estimate the overall, age-, sex-, epidemic
38	period- and cause-specific excess mortality in 2022 in Hong Kong and compared
39	excess mortality to laboratory-confirmed COVID-19 mortality.
40	Methods: Negative binomial regression analysis was used to model time series of
41	weekly all-cause and cause-specific deaths from 2010 to 2021 to predict the weekly
42	number of deaths in 2022 against counterfactual baselines projected from the trends
43	in the absence of a pandemic. The estimated excess deaths were compared with
44	laboratory-confirmed COVID-19 deaths overall and by age and epidemic period.
45	Results: We estimated that there were 13,500 (95% CI: 13,400-13,600) excess
46	deaths in 2022, which was slightly higher than the 12,228 deaths recorded with
47	laboratory-confirmed COVID-19, with the majority of the excess deaths and
48	laboratory-confirmed deaths occurring among older adults. The increased number of
49	excess deaths over laboratory-confirmed COVID-19 deaths was most substantial
50	from February to April 2022 (a difference of 847 deaths), when the largest Omicron
51	wave peaked. Most of the excess deaths (78%) were from respiratory causes, while
52	10% were from cardiovascular causes. A slight reduction in malignant neoplasm
53	mortality was identified among older adults in 2022.
54	Conclusions: A substantial increase in population mortality was identified in 2022
55	in Hong Kong, slightly larger than the laboratory-confirmed COVID-19 deaths.
56	Apart from the possibility of underdiagnosis, excess deaths might also be attributed
57	to the overload of healthcare resources during the pandemic. Deaths from
58	COVID-19 may have displaced some deaths that would otherwise have occurred

- 59 due to other causes although we did not find evidence of substantial mortality
- 60 displacement.
- 61
- 62

63 INTRODUCTION

64 Since the emergence of SARS-CoV-2 at the end of 2019, millions of COVID-19 65 deaths with infection of the virus have been recorded globally (1). However, the 66 reported number may not represent the full mortality impact associated with the COVID-19 pandemic for several reasons. First, some COVID-19 deaths may be 67 68 assigned to other causes due to misclassification or misdiagnosis, particularly during 69 the early phase of the pandemic when the diagnostic capacity was more limited (2, 3). Second, there may have been indirect health impact due to the disruption of 71 essential medical services due to pressure on the health-system (3), changes in 72 medical behavior resulting from difficulty in accessing healthcare services (4, 5), or 73 fear of getting infected in medical institutions or delays in seeking healthcare under 74 stay-at-home policies or other social distancing measures (5, 6). Excess mortality is 75 the difference between the observed and expected mortality obtained under some 76 counterfactual scenario (7, 8). This indicator has long been used to estimate the 77 disease burden of past health crises or pandemics based on mortality time-series 78 (8-10). For the COVID-19 pandemic, the World Health Organization (WHO) 79 estimated 14.83 million excess deaths in 2020 and 2021, which is 2.74 times higher 80 than the reported deaths (5.42 million) from laboratory-confirmed SARS-CoV-2 81 infections (3).

82

Hong Kong adopted an elimination strategy during the COVID-19 pandemic in 2020 and 2021 (11). Individual and population interventions were introduced, such as universal isolation of confirmed cases, strict quarantine of close contacts, school closures and other compulsory social distancing measures (12). These measures effectively controlled pre-Omicron transmission resulting in 181 (2 per 100,000)

88	local laboratory-confirmed COVID-19 deaths in 2020 and 30 (0.4 per 100,000) in
89	2021 (12). However, our previous study estimated an estimated 1,800 excess deaths
90	from diseases other than COVID-19 in 2020, potentially related to delays or
91	reductions in healthcare seeking as a consequence of strict public health and social
92	measures (5). In early 2022 Hong Kong experienced a very large Omicron epidemic
93	in the early period of the year, with over 2 million confirmed COVID-19 cases (by
94	RT-PCR or rapid antigen tests) and 10,000 deaths reported (136 per 100,000) (12).
95	
96	The considerable excess mortality identified during the elimination phase with
97	minimal transmission of COVID-19 (5) prompted us to investigate mortality impact
98	of COVID-19 over a much larger epidemic caused by Omicron subvariants in Hong

cause of death, and comparing the excess mortality to the reported fatal cases withconfirmed COVID-19.

Kong by estimating the excess mortality in 2022 by age, sex, epidemic period, and

102

99

103 METHODS

- 104 Sources of data
- 105 Individual death data from 2010 to 2022 were obtained from the Census and
- 106 Statistics Department of Hong Kong. Weekly mortality data were aggregated into
- 107 groups of age (0-4, 5-14, 15-44, 45-64, 65-79 and ≥80), sex, and cause of death.
- 108 Cause of deaths were coded by the International Classification of Diseases Tenth
- 109 Revision (ICD-10) and grouped into: all causes (A00-Z99), and the following major
- 110 causes: respiratory diseases (J00-J99), malignant neoplasms (C00-C97),
- cardiovascular diseases (I00-I99), kidney diseases (N00-N07, N17-N19, N25-N27),
- external causes (S00-T88), diabetes mellitus (E10-E14), and other causes (including

113	diseases of the digestive system, mental and behavioral disorders, certain infectious
114	and parasitic diseases, diseases of the nervous system, et al.). Data on individual
115	patients with laboratory-confirmation of SARS-CoV-2 in 2022 were obtained from
116	the Hong Kong Hospital Authority (HA), Centre for Health Protection and Deaths
117	Registry (13). Epidemiological information of individual patients was provided in
118	the database, including age, sex, date of laboratory confirmation, occurrence of
119	death in-hospital or out-of-hospital. In this analysis, a laboratory-confirmed
120	COVID-19 death was defined as a person who had a positive RT-qPCR result
121	testing for SARS-CoV-2 with a respiratory specimen collected within 28 days
122	before or seven days after the date of death. The annual mid-year population data by
123	age and sex between 2010 and 2022 were collected from the Census and Statistics
124	Department (14).
125	
126	Statistical analysis

127 Weekly mortality risk was calculated by dividing the number of weekly deaths by 128 mid-year populations in Hong Kong, by age, sex, and cause of death. We applied 129 negative binomial regression models to the time series of weekly number of all-cause and disease-specific deaths from 2010 to 2021, assuming the temporal 131 mortality in 2010-21 extending to 2022. In each regression model, we included the 132 population size as an offset and accounted for long-term trends using the calendar 133 year. Fourier terms with the variable "week" were included in the regression models 134 to allow for annual seasonality. Another covariate was included in the model to 135 account for changes in the mortality trend in Hong Kong since the emergence of 136 SARS-CoV-2 in January 2020. The COVID-19-associated excess mortality risk was 137 calculated by subtracting the predicted weekly mortality risk from the fitted

138	regression model from the observed weekly mortality risk. Performance of the
139	model was examined using the Akaike Information Criterion (AIC) during the
140	model proceeding.
141	
142	In 2022, Hong Kong experienced two major epidemics driven by Omicron
143	subvariants, including the largest wave during February - April and a smaller wave
144	from November onwards. We defined weeks 1-26 as period 1 (wave 5), weeks
145	27-45 as period 2 (wave 6a), and weeks 46-52 as period 3 (wave 6b) (12). The
146	all-cause excess mortality was estimated for these three periods using the same
147	method described above and compared with the reported COVID-19 mortality for
148	each period. Further technical details of the statistical methods are provided in the
149	Appendix. All statistical analyses were conducted in R, version 4.1.0 (R Foundation
150	for Statistical Computing, Vienna, Austria).
151	
152	Our study received ethical approval from the Institutional Review Board of the
153	University of Hong Kong/Hospital Authority Hong Kong West Cluster.
154	
155	RESULTS
156	An overall increasing trend of annual mortality in Hong Kong was observed from
157	2010 through to 2022, with a slight increase from 596 per 100,000 population in
158	2010 to 645 in 2019, and a sharp rise to 864 in 2022 (Figure 1A). Prior to 2022, the
159	weekly mortality peaked in late December to January every year while a prominent
160	peak was noted in February - March in 2022, in line with the trend in confirmed
161	COVID-19 case numbers (Figure 1A, Figure 1B). In 2022, people aged 80 years or
162	above had the highest mortality, followed by individuals aged 65-79 years, and the

163	mortality risk was generally higher in males than females. The top three causes of
164	death in 2022 were respiratory diseases (302 per 100,000 population), malignant
165	neoplasms (202), and cardiovascular diseases (152), which differed from 2020 and
166	2021 when malignant neoplasms (197 and 203 in 2020 and 2021, respectively) were
167	the leading cause, followed by respiratory (151 and 157) and cardiovascular (137
168	and 140) diseases (Table S1).
169	
170	In total, there were 63,484 deaths (864 per 100,000 population) recorded by the
171	death registry in 2022. With the predicted counterfactual mortality baseline of
172	49,966 deaths (680, 95% CI: 678, 682, per 100,000 population), the excess mortality
173	in 2022 was estimated to be 184 per 100,000 (95% CI: 182, 186), equating to an
174	estimated 13,518 (95% CI: 13,403-13,633) additional deaths and a 27% increase in
175	all-cause mortality (Figures 1A and 2A, Table S2). People aged 80 years or above
176	showed the highest excess mortality risk in 2022 (2,354 per 100,000 population, 95%
177	CI: 2,330-2,378) throughout the three defined epidemic periods, followed by 65-74
178	years (260, 95% CI: 255-265), accounting for 68% and 22% of all excess deaths in
179	this year, respectively (Figure 2, Table S2). Overall males (232, 95% CI: 230-235
180	per 100,000) showed a higher excess mortality than females (143, 142-145) and sex
181	differences were indicated in most age groups, particularly people over 80 years
182	(2,897 excess deaths, 95% CI: 2,858-2,935 for males vs 1,960, 1,930-1,991 for
183	females). Less than 2% of the estimated excess deaths were identified in individuals
184	younger than 45 years (Figure S1A, Table S2).
185	
186	Compared with 12,228 individuals died with confirmed COVID-19 recorded in

187 2022 (166 deaths per 100,000 population, 95% CI: 164-169), the slightly higher

188	estimate of the excess mortality (184 per 100,000 population, 95% CI: 182-186) for
189	the same year shared similar age-, sex-, and period-specific patterns (Figure 2A).
190	Older adults over 80 years of age contributed to most of the differences between
191	excess deaths and the reported COVID-19 deaths (44%, 567/1290 deaths increased),
192	followed by those aged 65-79 years (287, 22%) and 45-64 years (236, 18%) (Figure
193	2A, Table S3). The excess mortality was also higher than the reported COVID-19
194	mortality for both males (232 vs 212 per 100,000 population) and females (143 vs
195	128). The sex- and age-specific analysis indicated that 63% of the overall difference
196	between the excess and reported deaths in females was attributed to patients over 80
197	years of age. However, the death difference in males was contributed by the four
198	adult groups, 15-44 (20%), 45-64 (30%), 65-79 (23%), and those over 80 years
199	(27%) similarly (Figure S2, Figure S3).
200	
201	Among the 7 causes of death investigated in this study, excess mortality was
202	identified in 2022 for these major causes except for malignant neoplasms (Figure 3,
203	Figure S4). The highest excess mortality risk was estimated for respiratory diseases
204	(145 per 100,000 population, 95% CI: 144-146) and cardiovascular diseases (17, 95%
205	CI: 16-18), representing 92% and 13% increase from the estimated baseline,
206	respectively. The additional deaths from the two causes accounted for 88% of all
207	excess deaths estimated for 2022 (Figure 3, Table S2). The reported mortality from
208	malignant neoplasms (202 per 100,000 population) was slightly lower than the
209	predicted (205, 95% CI: 204-207), with the largest reduction in people over 80 years
210	(reduced by 25 per 100,000 population, 95% CI: 18-32), followed by those 65-79
211	years (6, 95% CI: 3-9) (Figure 3B, Table S2).

213	The higher number of excess deaths over reported COVID-19 deaths in 2022 was
214	most prominent in period 1 (weeks 1-26, 847 more deaths, 95% CI: 762-932),
215	accounting for about 66% (847/1290) of the overall difference (Figure 2B-D, Table
216	S3). Among these, the majority occurred in older adults over 80 years of age
217	(624/847,74%) (Figure 2B). During period 2, however, the estimated excess deaths
218	in people over 80 years were lower than the reported COVID-19 deaths (-128, 95%
219	CI: -179, -77) although the age group 65-79 years showed the highest increase in the
220	number of excess deaths over the reported COVID-19 deaths (151, 120-183) among
221	all age groups, followed by 15-44 years (116, 109-123) (Figure 2C, Table S3). In
222	period 3, people aged over 80 (over 71, 34-107) and 45-64 (over 73, 60-86) showed
223	a similar number of increases (Figure 2D, Table S3). The increased number of
224	excess deaths over confirmed COVID-19 deaths was identified in all epidemic
225	periods for both males and females (Figure S2, Figure S3).

226

227 **DISCUSSION**

228 We estimated that the excess mortality associated with the COVID-19 pandemic in 229 2022 was 184 (95% CI: 182, 186) per 100,000 population, 27% higher than the 230 baseline mortality predicted for the year based on the historical trend. The estimated 231 excess mortality was not only identified in causes of respiratory diseases, but also 232 other causes, such as cardiovascular diseases, accounting for 10% of the overall 233 excess deaths in 2022, particularly among older adults at age of 80 years or above. A 234 slightly higher number of excess deaths than the reported COVID-19 deaths was 235 observed mainly in the older adults during the peak of the Omicron BA.2 wave in 236 early 2022.

237

238 A close concordance was indicated in our study between the estimated number of 239 excess deaths and the officially recorded deaths with a confirmation of COVID-19 240 in 2022. Globally, a report from the World Health Organization found that the 241 excess mortality in 2020 and 2021 was 2.74 times higher than the reported 242 COVID-19 mortality (3). A series of excess mortality studies conducted in the US 243 found that among the overall excess deaths estimated during the pandemic, only 244 65%-72% were attributed to COVID-19 (15-18). Hong Kong had very substantial 245 laboratory testing capacity, testing approximately 3% of the population each day 246 during March 2022 which included routine on-admission testing in hospitals (12). 247 Nevertheless in our previous analysis of population mortality in Hong Kong in 2020 248 we found an increase in cardiovascular mortality with very few COVID-19 deaths, 249 potentially attributable to changes in healthcare seeking behaviours or disruption in 250 care for older individuals with cardiovascular diseases (5), and this has also been 251 reported in other locations (15-19). In the present analysis we did not observe a 252 substantial indirect impact of the pandemic on mortality from other causes, although 253 some indirect impact likely occurred and is included as part of the overall excess 254 mortality.

255

One notable difference between the substantial mortality impact of COVID-19 in Hong Kong compared with other locations is that the impact in Hong Kong occurred in 2022, whereas highest excess mortality rates in the pandemic in other parts of the world generally occurred in 2020 and early 2021 prior to the availability of COVID-19 vaccines (3, 21, 22). We have reported separately that vaccination uptake in older adults in Hong Kong was low for various reasons (12, 23, 24), leading to a substantial mortality impact in the Omicron BA.2 wave in March-April

263 2022 (25). We also reported that case fatality rates increased by 3-fold during the

264 peak weeks of the Omicron wave compared to earlier and later in that epidemic (26),

likely due to the extreme pressure on healthcare resources at that time.

266

267 The higher number of excess deaths than the deaths with confirmed COVID-19 in 268 Hong Kong in 2022 identified mainly in older adults during the peak of the Omicron 269 wave in this study might also be the consequence of the large number of infections 270 and the relatively lower vaccination coverage in the elderly (12). In contrast, 271 countries such as Canada and Norway estimated a lower excess all-cause mortality 272 during the Omicron epidemic than the reported COVID-19 mortality (18). It could 273 be explained that many laboratory-confirmed COVID-19 deaths particularly in very 274 frail older adults were actually deaths "with COVID-19" rather than "due to 275 COVID-19", which were counted as COVID-19 deaths but not changing the overall 276 mortality rate (2, 20). Consequently, the death rate from causes other than 277 COVID-19 may be reduced due to mortality displacement, and this might explain 278 the reduction we observed in deaths from malignant neoplasms in the Hong Kong 279 population throughout 2022 as well as the relatively lower excess deaths in older 280 adults over months after the largest omicron wave in comparison with the confirmed 281 COVID-19 deaths.

282

A number of limitations exist in this study. First, we were not able to separate the direct impact from indirect impact of the COVID-19 pandemic in the estimated excess deaths. Previously Lee et al. intended to achieve the separation by including covariates representing the two types of impact in the regression model (19). Future studies are needed to clearly define the different impact and develop valid methods

288 to make a causal inference on the health impact caused by COVID-19. Second, the 289 accuracy of the estimated excess mortality for some defined groups in the analysis, 290 such as children aged 5-14 years, might be limited by the small numbers of weekly 291 deaths. Third, weekly death data from 2010 to 2021 was used to obtain the predicted 292 weekly deaths in 2022. Different from previous studies which often used the data 293 before 2020 as the mortality baseline, our baseline was determined based on the 294 historical mortality trend as well as allowing for possible changes during the 295 COVID-19 pandemic. Therefore, a direct comparison of our estimates with others 296 may not be entirely appropriate.

297

In conclusion, a substantial number of excess deaths were identified in Hong Kong during a large Omicron predominant COVID-19 epidemic, and the slightly higher number of excess deaths over reported laboratory-confirmed COVID-19 deaths demonstrated the importance of pandemic responses with effective pharmaceuticals in particular vaccines in reducing the overall health burden especially in older adults. We did not identify substantial mortality displacement from other causes of death in 2022.

305 ACKNOWLEDGMENTS

306 The authors thank Julie Au for technical support.

307

308 FUNDING

- 309 This project was financially supported by the Health and Medical Research Fund
- from the Health Bureau of the Government of the Hong Kong Special
- Administrative Region (grant no: CID-HKU2-14), and by a grant from the Research
- 312 Grants Council of the Hong Kong Special Administrative Region, China (Project No.
- 313 T11-705/21-N).

314

315 AUTHOR CONTRIBUTIONS

All authors meet the ICMJE criteria for authorship. The study was conceived by

- BJC, PW and WY. HX, JYW, AHTL and JKC analyzed the data. HX wrote the first
- draft of the manuscript. All authors provided critical review and revision of the textand approved the final version.

320

321 DATA SHARING STATEMENT

Restrictions apply to the availability of these data. The mortality data are available for access with the permission from the Hospital Authority and the Census and Statistics Department of Hong Kong.

325

326 POTENTIAL CONFLICTS OF INTEREST

- 327 B.J.C. has consulted for AstraZeneca, Fosun Pharma, GlaxoSmithKline, Haleon,
- 328 Moderna, Novavax, Pfizer, Roche, and Sanofi Pasteur. All other authors report no
- 329 potential conflicts of interest.

331 **REFERENCES**

- 1. World Health Organization. WHO COVID-19 dashboard.
- 333 <u>https://data.who.int/dashboards/covid19/cases?n=c</u>. Accessed 3 May 2024.
- 2. Stokes AC, Lundberg DJ, Elo IT, Hempstead K, Bor J, Preston SH. COVID-19
- and excess mortality in the United States: A county-level analysis. PLoS medicine.
- 336 2021;18(5):e1003571.
- 337 3. Msemburi W, Karlinsky A, Knutson V, Aleshin-Guendel S, Chatterji S,
- 338 Wakefield J. The WHO estimates of excess mortality associated with the COVID-19
- 339 pandemic. Nature. 2023;613(7942):130-7.
- 4. Marijon E, Karam N, Jost D, Perrot D, Frattini B, Derkenne C, et al.
- 341 Out-of-hospital cardiac arrest during the COVID-19 pandemic in Paris, France: a
- 342 population-based, observational study. The Lancet Public health.
- 343 2020;5(8):e437-e43.
- 5. Xin H, Wu P, Wong JY, Cheung JK, Lau EHY, Leung GM, et al.
- 345 Hospitalizations and mortality during the first year of the COVID-19 pandemic in
- Hong Kong, China: An observational study. The Lancet regional health Western
- 347 Pacific. 2023;30:100645.
- 348 6. Kiss P, Carcel C, Hockham C, Peters SAE. The impact of the COVID-19
- 349 pandemic on the care and management of patients with acute cardiovascular disease:
- a systematic review. European heart journal Quality of care & clinical outcomes.
- **351 2021;7(1):18-27**.
- 352 7. Woodruff BA. Interpreting mortality data in humanitarian emergencies. Lancet
- 353 (London, England). 2006;367(9504):9-10.
- 8. Leon DA, Shkolnikov VM, Smeeth L, Magnus P, Pechholdová M, Jarvis CI.
- 355 COVID-19: a need for real-time monitoring of weekly excess deaths. Lancet

- 356 (London, England). 2020;395(10234):e81.
- 357 9. Murray CJ, Lopez AD, Chin B, Feehan D, Hill KH. Estimation of potential
- 358 global pandemic influenza mortality on the basis of vital registry data from the
- 359 1918-20 pandemic: a quantitative analysis. Lancet (London, England).
- 360 2006;368(9554):2211-8.
- 10. Beaney T, Clarke JM, Jain V, Golestaneh AK, Lyons G, Salman D, et al. Excess
- 362 mortality: the gold standard in measuring the impact of COVID-19 worldwide?
- Journal of the Royal Society of Medicine. 2020;113(9):329-34.
- 11. Baker MG, Wilson N, Blakely T. Elimination could be the optimal response
- 365 strategy for covid-19 and other emerging pandemic diseases. BMJ (Clinical research
- d). 2020;371:m4907.
- 12. Yang B, Lin Y, Xiong W, Liu C, Gao H, Ho F, et al. Comparison of control and
- transmission of COVID-19 across epidemic waves in Hong Kong: an observational
- 369 study. The Lancet regional health Western Pacific. 2024;43:100969.
- 13. McMenamin ME, Nealon J, Lin Y, Wong JY, Cheung JK, Lau EHY, et al.
- 371 Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac
- against COVID-19 in Hong Kong: a population-based observational study. The
- 373 Lancet Infectious diseases. 2022;22(10):1435-43.
- 14. Census and Statistics Department. Population Estimates.
- 375 <u>https://www.censtatd.gov.hk/en/scode150.html</u>. Accessed 3 May 2024.
- 15. Woolf SH, Chapman DA, Sabo RT, Weinberger DM, Hill L. Excess Deaths
- 377 From COVID-19 and Other Causes, March-April 2020. Jama. 2020;324(5):510-3.
- 16. Woolf SH, Chapman DA, Sabo RT, Weinberger DM, Hill L, Taylor DDH.
- 379 Excess Deaths From COVID-19 and Other Causes, March-July 2020. Jama.
- 380 2020;324(15):1562-4.

- 381 17. Woolf SH, Chapman DA, Sabo RT, Zimmerman EB. Excess Deaths From
- 382 COVID-19 and Other Causes in the US, March 1, 2020, to January 2, 2021. Jama.
- 383 2021;325(17):1786-9.
- 18. Bilinski A, Thompson K, Emanuel E. COVID-19 and Excess All-Cause
- Mortality in the US and 20 Comparison Countries, June 2021-March 2022. Jama.
- 386 2023;329(1):92-4.
- 19. Lee WE, Woo Park S, Weinberger DM, Olson D, Simonsen L, Grenfell BT, et al.
- 388 Direct and indirect mortality impacts of the COVID-19 pandemic in the United
- 389 States, March 1, 2020 to January 1, 2022. eLife. 2023;12.
- 390 20. Acosta E. Global estimates of excess deaths from COVID-19. Nature.
- 391 2023;613(7942):31-3.
- 392 21. Estimating excess mortality due to the COVID-19 pandemic: a systematic
- analysis of COVID-19-related mortality, 2020-21. Lancet (London, England).
- 394 2022;399(10334):1513-36.
- 395 22. Pallari CT, Achilleos S, Quattrocchi A, Gabel J, Critselis E, Athanasiadou M, et
- al. Magnitude and determinants of excess total, age-specific and sex-specific
- all-cause mortality in 24 countries worldwide during 2020 and 2021: results on the
- impact of the COVID-19 pandemic from the C-MOR project. BMJ global health.
- 399 2024;9(4).
- 400 23. Xiao J, Cheung JK, Wu P, Ni MY, Cowling BJ, Liao Q. Temporal changes in
- 401 factors associated with COVID-19 vaccine hesitancy and uptake among adults in
- 402 Hong Kong: Serial cross-sectional surveys. The Lancet regional health Western
- 403 Pacific. 2022;23:100441.
- 404 24. Yuan J, Lam WWT, Xiao J, Ni MY, Cowling BJ, Liao Q. Why Do Chinese
- 405 Older Adults in Hong Kong Delay or Refuse COVID-19 Vaccination? A Qualitative

- 406 Study Based on Grounded Theory. The journals of gerontology Series B,
- 407 Psychological sciences and social sciences. 2023;78(4):736-48.
- 408 25. Mefsin YM, Chen D, Bond HS, Lin Y, Cheung JK, Wong JY, et al.
- 409 Epidemiology of Infections with SARS-CoV-2 Omicron BA.2 Variant, Hong Kong,
- 410 January-March 2022. Emerging infectious diseases. 2022;28(9):1856-8.
- 411 26. Wong JY, Cheung JK, Lin Y, Bond HS, Lau EHY, Ip DKM, et al. Intrinsic and
- 412 Effective Severity of Coronavirus Disease 2019 Cases Infected With the Ancestral
- 413 Strain and Omicron BA.2 Variant in Hong Kong. The Journal of infectious diseases.
- 414 2023;228(9):1231-9.

416 FIGURE LEGENDS

417 Figure 1. The overall trend of mortality and excess deaths in 2022 in Hong

418	Kong. A) Weekly observed (black dots) and predicted (red solid line and the pink
419	shaded area show the mean predicted weekly mortality and 95% confidence
420	intervals, respectively) mortality from 2010 to 2022 in Hong Kong. B) Predicted
421	weekly numbers of excess deaths (red solid line and the pink shaded area show the
422	mean weekly numbers of excess deaths and 95% CI, respectively), weekly numbers
423	of reported COVID-19 deaths (purple bars) and weekly numbers of locally infected
424	COVID-19 cases in Hong Kong in 2022.
425	

Figure 2. Overall and age-specific excess mortality and reported COVID-19 mortality in 2022. A) Comparison of excess mortality and reported COVID-19 mortality overall and by age in 2022. B) Comparison of excess mortality and reported COVID-19 mortality overall and by age in weeks 1-26 in 2022. C) Comparison of excess mortality and reported COVID-19 mortality overall and by age in weeks 27-45 in 2022. D) Comparison of excess mortality and reported COVID-19 mortality overall and by age in weeks 46-52 in 2022.

433

Figure 3. Cause-specific excess mortality by age and sex in Hong Kong in 2022. A) Excess mortality by age and sex for respiratory diseases. B) Malignant neoplasms. C) Cardiovascular diseases. D) Kidney diseases. E) External causes. F) Diabetes mellitus. G) Others (deaths from all other causes except those causes shown in panels A-F).

(which was not certified by performed on the properties of the pro

A: Weekly observed and predicted mortality from 2010 to 2022



Weeks from 2010 to 2022



Weeks in 2022









